Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Roche’s High Stakes Gambit For Genentech

Executive Summary

With Roche's unsolicited attempt to buy out Genentech's minority shareholders for $89 dollars a share, a bid totaling nearly $44 billion, the company is wagering heavily that it will not destroy one of the industry's most successful pharma-biotech collaborations. But has Roche laid out a straight flush or lost its ace to a bluff

Related Content

Clinical Development Setbacks, Pricing Pressures Hit Roche
Genentech Reorganization Signals Shift To New Model Under Roche
Blinding Them With Science: Genentech Tries To Win Shareholders Over
Roche Ups Negotiating Ante With Hostile Bid For Genentech
Roche/Genentech: A Case Study For Future Hostile Offers
Devilish Details: Icahn Looks To Boost Bristol/ImClone Offer
The Next Bristol/ImClone? “Standstill” Provisions Complicate Other Deals
In Bid For Genentech, How High Can Roche Go?
Pipeline Dreams: GSK’s Witty Outlines Plans To Lower Phase III Attrition
After Roche/Genentech: Pharma's Focus on Efficiencies, Not Innovation



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts